Novartis Zelnorm "Marginal" Efficacy May Be Due To Trial Design, FDA Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
"Marginal" efficacy seen with Novartis’ constipation-predominant irritable bowel syndrome agent Zelnorm could be a result of trial design, FDA review documents suggest.